Anlotinib plus chemotherapy for <scp>T790M</scp> ‐negative <scp> <i>EGFR</i> </scp> ‐mutant <scp>non‐sqNSCLC</scp> resistant to <scp>TKIs</scp> : A multicenter phase 1b/2 trial-Reference-Cited by-同舟云学术

Anlotinib plus chemotherapy for T790M ‐negative EGFR ‐mutant non‐sqNSCLC resistant to TKIs : A multicenter phase 1b/2 trial

Published:2022-11-08 Issue:24 Volume:13 Page:3496-3503
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Li Juan¹^ORCID,Tian Yuke¹,Zheng Min¹,Ge Jun¹,Zhang Jiliang²,Kong Dejun³,Chen Mei⁴,Yu Ping¹

Affiliation:

1. Department of Medical Oncology Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China Chengdu China

2. Department of Oncology Chengdu Seventh People's Hospital, Chengdu Tumor Hospital Chengdu China

3. Department of Oncology The Second Affiliated Hospital of Chengdu College, Nuclear Industry 416 Hospital Chengdu China

4. Department of Respiratory Medicine Chengdu Fifth People's Hospital Chengdu China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14713

Reference24 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Histologic Lung Cancer Incidence Rates and Trends Vary by Race/Ethnicity and Residential County

3. ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer

4. Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer

5. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term survival in a patient with metastatic parathyroid carcinoma harboring an EGFR sensitizing mutation: a case report;Journal of International Medical Research;2024-07

2. Etoposide soft capsule combined with anlotinib in the third-line treatment of advanced non-small cell lung cancer: a retrospective cohort study;Journal of Thoracic Disease;2023-10